Why MannKind Corporation Popped Today
Shares of MannKind Corporation (NASDAQ: MNKD), a commercial-stage biopharma focused on inhaled insulin, rose as much as 13% in afternoon trading on Monday. Shareholders can largely thank two positive developments for the jump.
First, MannKind announced that the FDA has OK'd an update to Afrezza's prescribing information. Here's a quick review of the labeling update:
Here's what MannKind's CEO Michael Castagna had to say about this labeling change on a special investor call:
Source: Fool.com
Abbott Laboratories Stock
€96.93
-0.540%
With 19 Buy predictions and not the single Sell prediction the community is currently very high on Abbott Laboratories.
As a result the target price of 116 € shows a slightly positive potential of 19.67% compared to the current price of 96.93 € for Abbott Laboratories.
